Anti Inflammatory News and Research

RSS

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Some components of the onion have antioxidant and antimicrobial properties, making it possible to use this bulb for food preservation. This is demonstrated by researchers from the Polytechnic University of Catalu-a and the University of Barcelona in a study that has just been published in the International Journal of Food Science and Technology.

16 Apr 2010

Low levels of vitamin D associated with lower lung function in children with asthma

Low levels of vitamin D are associated with lower lung function and greater medication use in children with asthma, according to researchers at National Jewish Health. In a paper published online this week in the Journal of Allergy & Clinical Immunology, Daniel Searing, MD, and his colleagues also reported that vitamin D enhances the activity of corticosteroids, the most effective controller medication for asthma.

16 Apr 2010

Spring is busting out all over - and so are eye allergies

Ah, spring. The time of year when trees and flowers bloom sending pollen into the air and causing sneezing, runny noses and watery eyes. The Asthma & Allergy Foundation of America estimates that 1 in 5 individuals are affected by eye allergies.

15 Apr 2010

Use of silver dressing in burn cases questioned

The use of expensive silver dressing in burn cases is being brought under the scanner by an editorial in the Drug and Therapeutics Bulletin. The NHS has increased its spending from £23 million in 2005 to around £25 million in 2006/7 on such products. The author asks if expensive silver dressing is really justified when cheaper alternatives are available.

15 Apr 2010

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immuno-inflammatory diseases and cancer, today announced the upcoming presentations of clinical data from the company's two lead programs, VB-201 and VB-111, at premier dermatology and cancer research medical meetings this spring.

13 Apr 2010

XOMA expands anti-inflammatory antibody intellectual property portfolio

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that the U.S. Patent and Trademark Office has issued two new patents that significantly expand the company's intellectual property portfolio relating to its anti-inflammatory antibody, XOMA 052, that targets interleukin-1 beta (IL-1 beta).

13 Apr 2010

BioElectronics plans to move trading of common shares to OTCBB quotation system

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the organization is in the process of working with market makers to move the trading of its common shares to the OTCBB quotation system. This comes about as a result of the recent completion of full financial audits for the years 2005 through 2009 and the filing of Form 10K with the U.S. Securities and Exchange Commission. BioElectronics is now a fully reporting company.

13 Apr 2010

Study identifies pathway linked to rheumatoid arthritis

Investigators from Hospital for Special Surgery have identified a pathway involved in turning off inflammation that does not work properly in people with inflammatory arthritis. The finding, reported in the April 23 issue of the journal Immunity, could lead to the development of new therapeutic approaches to treating arthritis in the future.

13 Apr 2010

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Aeolus Pharmaceuticals, Inc. announced today that a second study of its lead drug, AEOL 10150, has been initiated by the National Institutes of Health's (NIH), National Institute of Allergy and Infectious Diseases (NIAID) Radiation/Nuclear Medical Countermeasures development program as a countermeasure for radiation exposure to the gastrointestinal (GI) tract.

13 Apr 2010

Cytomedix reports going concern qualification in Annual Report for fiscal year ended December 31, 2009

Cytomedix, Inc. announced today that its audited financial statements for the fiscal year ended December 31, 2009, included in its Annual Report on Form 10-K filed on March 29, 2010, contained a going concern qualification from its independent registered accounting firm.

13 Apr 2010

Cytomedix to acquire Sorin's Angel blood separation system and activAT Autologous Thrombin Processing Kit

Cytomedix, Inc., a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced the closing of an agreement with Sorin Group, a global leader in the treatment of cardiovascular diseases, to acquire the Angel® Whole Blood Separation System and activAT® Autologous Thrombin Processing Kit for $7 million in cash, to be paid in installments over the next two and one-half years.

13 Apr 2010

Asthma-like symptoms in infants and toddlers is often RAD

Your child is wheezing. Your child must have asthma, right? Not always, says Julie Koehler, professor and chair of the Department of Pharmacy Practice in Butler University's College of Pharmacy and Health Sciences and clinical pharmacy specialist in family medicine at Clarian Health.

12 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, today announced initial results from a Phase I multicenter safety study of PDA-001 in treatment-resistant Crohn's Disease. PDA-001 is an immunomodulatory therapy consisting of human placenta-derived cells obtained from CCT's proprietary processes.

9 Apr 2010

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

If you're serious about losing weight, check out recent studies done in Elvira de Mejia's University of Illinois laboratory. Her research provides insight into the way a certain type of soy protein inhibits fat accumulation and reduces inflammation.

2 Apr 2010

Study shows drinking cherry juice can boost recovery time for Marathon runners

Runners taking part in the April 2010 London Marathon can boost their recovery time by drinking tart cherry juice before and after the race, according to a researcher at Northumbria University.

2 Apr 2010

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

Eli Lilly and Company announced today that its chemotherapy ALIMTA® (pemetrexed for injection) received a positive "Final Appraisal Determination" from the United Kingdom's National Institute for Health and Clinical Excellence (NICE).

2 Apr 2010

BioElectronics files Form 10K with Securities and Exchange Commission

BioElectronics Corp., the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announced the completion of its full year audit and the filing of Form 10K with the Securities and Exchange Commission. BioElectronics is now a fully reporting company.

1 Apr 2010

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Xanodyne Pharmaceuticals, Inc., an integrated specialty pharmaceutical company with both development and commercial capabilities focused on women's healthcare and pain management, today announced that it has signed a co-promotion agreement for Zipsor™ (diclofenac potassium) Liquid Filled Capsules with Ferring Pharmaceuticals Inc., a global bio-pharmaceutical company, headquartered in Switzerland.

1 Apr 2010

Anti Inflammatory News and Research

Flavonoids of onion are natural alternative to artificial additives in food industry: Study

Low levels of vitamin D associated with lower lung function in children with asthma

Spring is busting out all over - and so are eye allergies

Use of silver dressing in burn cases questioned

VBL Therapeutics announces upcoming presentations at premier dermatology and cancer research meetings

XOMA expands anti-inflammatory antibody intellectual property portfolio

BioElectronics plans to move trading of common shares to OTCBB quotation system

Study identifies pathway linked to rheumatoid arthritis

NIAID funds second study of Aeolus Pharmaceuticals' AEOL 10150 as potential countermeasure to GI-ARS

Cytomedix reports going concern qualification in Annual Report for fiscal year ended December 31, 2009

Cytomedix to acquire Sorin's Angel blood separation system and activAT Autologous Thrombin Processing Kit

Asthma-like symptoms in infants and toddlers is often RAD

Tβ4 therapy for ocular disorders closer to reality

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Encouraging results from CCT's Phase I study of PDA-001 for treatment-resistant Crohn's Disease

Researchers identify soy peptides that inhibit fat accumulation and reduce inflammation

Study shows drinking cherry juice can boost recovery time for Marathon runners

UK NICE recommends Eli Lilly's ALIMTA as maintenance therapy for nonsquamous NSCLC

BioElectronics files Form 10K with Securities and Exchange Commission

Xanodyne Pharmaceuticals, Ferring Pharmaceuticals sign co-promotion agreement for Zipsor

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News